How Krishna Ella built Bharat Biotech and why the company is at a tipping point

Bharat Biotech’s Covaxin is India’s first indigenous coronavirus vaccine. The DCGI’s approval of Covaxin, despite it not having phase-3 clinical trial efficacy and safety data, stunned several vaccine experts. Many expressed doubts about the company’s clinical trial processes. A moment of triumph became a defensive one for Bharat Biotech’s founder-CMD M Krishna Ella.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3hY08gZ
via IFTTT